Neuroscientific Biopharmaceuticals (ASX:NSB) ROE % Adjusted to Book Value: -9.12% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neuroscientific Biopharmaceuticals ROE % Adjusted to Book Value?

Neuroscientific Biopharmaceuticals ASX:NSB ROE % Adjusted to Book Value is -9.12% as of Dec. 2025. The stock has 1 warning sign investors should review.

Neuroscientific Biopharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was -20.43%. Neuroscientific Biopharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was 2.24. Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -9.12%.

Neuroscientific Biopharmaceuticals ROE % Adjusted to Book Value Related Terms

Neuroscientific Biopharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuroscientific Biopharmaceuticals ROE % Adjusted to Book Value Chart

Neuroscientific Biopharmaceuticals Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -10.62 -21.88 -8.65 5.97 -9.74

Neuroscientific Biopharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.24 62.83 -14.69 -15.86 -9.12

ASX:NSB vs VRTX, REGN, RVMD: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuroscientific Biopharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value falls into.


Neuroscientific Biopharmaceuticals ROE % Adjusted to Book Value Calculation

Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-16.66% / 1.71
=-9.74%

Neuroscientific Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-20.43% / 2.24
=-9.12%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -9.12% mean?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a ROE % Adjusted to Book Value of -9.12% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Neuroscientific Biopharmaceuticals and its competitors.
Is Neuroscientific Biopharmaceuticals' ROE % Adjusted to Book Value too high?
Neuroscientific Biopharmaceuticals' current ROE % Adjusted to Book Value is -9.12%.
How does Neuroscientific Biopharmaceuticals' ROE % Adjusted to Book Value compare to VRTX and REGN?
Neuroscientific Biopharmaceuticals' ROE % Adjusted to Book Value of -9.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Neuroscientific Biopharmaceuticals and its competitors. Neuroscientific Biopharmaceuticals's current ROE % Adjusted to Book Value is -9.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current ROE % Adjusted to Book Value of -9.12%. The current ROE % Adjusted to Book Value is -9.12%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current ROE % Adjusted to Book Value is -9.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuroscientific Biopharmaceuticals Business Description

Address 216 Street Georges Terrace, Level 4, Perth, WA, AUS, 6000
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.